Advanced search
Publication Cover
Clinical Pharmacology: Advances and Applications Volume 13, 2021 - Issue
Submit an article Journal homepage
126
Views
3
CrossRef citations to date
0
Altmetric
Case Report

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion

Alexia Rouland1 Endocrinology Diabetics and Metabolic Disorders Department, Dijon University Hospital, Dijon, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0727-2052
ORCID Icon,
Benjamin Bouillet1 Endocrinology Diabetics and Metabolic Disorders Department, Dijon University Hospital, Dijon, France;2 French National Health and Medical Research Body Unit, Lipid-Nutrition-Cancer-1231, University of Burgundy, Dijon, 21000, FranceORCID Iconhttps://orcid.org/0000-0002-4317-6714
ORCID Icon,
Pauline Legris1 Endocrinology Diabetics and Metabolic Disorders Department, Dijon University Hospital, Dijon, France
,
Isabelle Simoneau2 French National Health and Medical Research Body Unit, Lipid-Nutrition-Cancer-1231, University of Burgundy, Dijon, 21000, FranceORCID Iconhttps://orcid.org/0000-0002-9092-1908
ORCID Icon,
Jean-Michel Petit1 Endocrinology Diabetics and Metabolic Disorders Department, Dijon University Hospital, Dijon, France;2 French National Health and Medical Research Body Unit, Lipid-Nutrition-Cancer-1231, University of Burgundy, Dijon, 21000, France
&
Bruno Vergès1 Endocrinology Diabetics and Metabolic Disorders Department, Dijon University Hospital, Dijon, France;2 French National Health and Medical Research Body Unit, Lipid-Nutrition-Cancer-1231, University of Burgundy, Dijon, 21000, FranceORCID Iconhttps://orcid.org/0000-0001-8957-629X
ORCID Icon
Pages 33-37 | Published online: 05 Feb 2021

References

  • Jabri AL, Bayard C. Nesidioblastosis associated with hyperinsulinemic hypoglycemia in adults: review of the literature. Eur J Intern Med. 2004;15(7):407–410. doi:10.1016/j.ejim.2004.06.01215581742
  • de Heide LJM, Laskewitz AJ, Apers JA. Treatment of severe postRYGB hyperinsulinemic hypoglycemia with pasireotide: a comparison with octreotide on insulin, glucagon, and GLP-1. Surg Obes Relat Dis. 2014;10(3):e31‑3. doi:10.1016/j.soard.2013.11.006
  • Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–3453. doi:10.1210/jc.2013-177123733372
  • Hendren NS, Panach K, Brown TJ, et al. Pasireotide for the treatment of refractory hypoglycaemia from malignant insulinoma. Clin Endocrinol (Oxf). 2018;88(2):341–343. doi:10.1111/cen.1350329055143
  • Tirosh A, Stemmer SM, Solomonov E, et al. Pasireotide for malignant insulinoma. Hormones. 2016;15(2):271–276.26732164
  • Lebowitz MR, Blumenthal SA. The molar ratio of insulin to C-peptide. An aid to the diagnosis of hypoglycemia due to surreptitious (or inadvertent) insulin administration. Arch Intern Med. 1993;153:650–655. doi:10.1001/archinte.1993.004100500820118439228
  • Okabayashi T, Shima Y, Sumiyoshi T, et al. Diagnosis and management of insulinoma. World J Gastroenterol. 2013;19:829–837. doi:10.3748/wjg.v19.i6.82923430217
  • Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999;48(1):77–85. doi:10.2337/diabetes.48.1.779892225
  • Singh V, Brendel MD, Zacharias S, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007;92(2):673–680. doi:10.1210/jc.2006-157817105845
  • Vergès B. Effects of anti-somatostatin agents on glucose metabolism. Diabetes Metab. 2017;43(5):411–415. doi:10.1016/j.diabet.2017.05.00328579289
  • Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol. 2012;212(1):49. doi:10.1530/JOE-11-022421987782
  • Boscaro M, Bertherat J, Findling J, et al. Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study. Pituitary. 2014;17(4):320–326. doi:10.1007/s11102-013-0503-323943009
  • Colao A, Petersenn S, Newell-Price J, et al. A 12-month Phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366(10):914–924. doi:10.1056/NEJMoa110574322397653
  • Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17(2):180–186. doi:10.1007/s11102-013-0483-323564338
  • Reznik Y, Bertherat J, Borson-Chazot F, et al. Management of hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab. 2013;39(1):34–41. doi:10.1016/j.diabet.2012.10.00523228667
  • Schwetz V, Horvath K, Kump P, et al. Successful medical treatment of adult nesidioblastosis with pasireotide over 3 years. Medicine (Baltimore). 2016;95(14):e3272. doi:10.1097/MD.000000000000327227057885

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.